The Emerging COVID-19 Therapy Market for Early Onset, Non-Hospitalized Patients: Three Segments to Watch

The Emerging COVID-19 Therapy Market for Early Onset, Non-Hospitalized Patients Three Segments to Watch

Three parallel worlds, segmented by socioeconomics, culture, and politics unfold during this pandemic, divided into what can be considered tier 1, tier 2, and tier 3 markets, where the former are the counties with the biggest economies, followed by the middle-tier developed or rapidly growing developing nations, followed finally by the latter lower-income nations. The stakes are large for the COVID-19 market for therapies treating early-onset, mild-to-moderate COVID-19, which is approximately 90% of incidents. Tier 1 counties’ demands for early-onset, mild-to-moderate COVID-19 therapy will be fulfilled by novel therapeutics developed by pharmaceutical companies, thanks in part to a confluence of forces that have successfully blocked the entrance of imminent low-cost options; while tier 2 will, in reality, reflect a mix of branded therapies localized in price and manufacturer along with moderately priced to low-cost generics with tier 3 overwhelmingly dependent on low-cost generic drugs such as ivermectin. Ivermectin’s mounting efficacy as exhibited in over 50 clinical trials, reveals increasing impact in places from Mexico City to Zimbabwe to India’s Uttar Pradesh s...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee